Spironolactone in patients with heart failure and preserved ejection fraction;Espironolactona en pacientes con insuficiencia cardiaca y fracción de eyección preservada

Revista Clinica Espanola

Volumn 216, Issue 2, 2016, Pages 111-

  Nunez J ^a   Nunez E ^a   Sanchis, J ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SPIRONOLACTONE;

HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; LETTER;

EID: 84959499776     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2015.10.005     Document Type: Letter

References (5)

1. C. Sánchez-Sánchez, H.F. Mendoza-Ruiz de Zuazu, F. Formiga, L. Manzano, L.M. Ceresuela, M. Carrera-Izquierdo, and et al. Espironolactona en pacientes con insuficiencia cardiaca y fracción de eyección preservada Rev Clin Esp 215 2015 301 307
2. M. Pintilie Análisis de riesgos competitivos Rev Esp Cardiol 64 2011 599 605
3. J.K. Rogers, S.J. Pocock, J.J. McMurray, C.B. Granger, E.L. Michelson, J. Östergren, and et al. Analysing recurrent hospitalizations in heart failure: A review of statistical methodology, with application to CHARM-Preserved Eur J Heart Fail 16 2014 33 40
4. S.D. Anker, and J.J. McMurray Time to move on from «time-to-first»: Should all events be included in the analysis of clinical trials Eur Heart J 33 2012 2764 2765
5. J.K. Rogers, P.S. Jhund, A.C. Perez, M. Böhm, J.G. Cleland, L. Gullestad, and et al. Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure) JACC Heart Fail 2 2014 289 297